Palbociclib单药或联合既往内分泌治疗用于HR阳性HER2阴性转移性乳腺癌:TREnd试验
TREnd是一项II期开放标签多中心随机研究,入组115例既往接受过1-2线内分泌治疗后进展的绝经后HR阳性/HER2阴性晚期乳腺癌患者,随机接受Palbociclib单药或联合既往内分泌治疗。联合治疗组与单药组CBR分别为54%与60%,中位PFS分别为10.8个月与6.5个月(HR 0.69,探索性P=0.12)。探索性分析显示既往内分泌治疗>6个月亚组联合治疗PFS获益(HR 0.53,探索性P=0.02)。
要点
- Palbociclib单药在中等程度经治的HR阳性/HER2阴性晚期乳腺癌中有临床活性,CBR 60%。
- 联合既往内分泌治疗组中位PFS 10.8个月,单药组6.5个月,差异未达统计学显著(探索性P=0.12)。
- 既往内分泌治疗>6个月亚组联合治疗PFS获益(HR 0.53,探索性P=0.02),≤6个月亚组未见获益。
核心结论
- Palbociclib单药在中等程度经治的ER阳性/HER2阴性晚期乳腺癌中具有临床活性。
- Palbociclib可能对既往内分泌治疗有持久缓解史的患者具有逆转内分泌耐药潜力。
研究设计与样本
- II期、开放标签、多中心随机研究,入组绝经后ER阳性/HER2阴性晚期乳腺癌患者。
- 患者既往接受过1或2线内分泌治疗后进展,按1:1随机接受Palbociclib单药或联合既往内分泌治疗。
- 主要终点为临床获益率(CBR),次要终点包括无进展生存期(PFS)。
- 2012年10月至2016年7月共随机115例患者。
主要发现
- 联合治疗组CBR为54%(95%CI 41.5-63.7),单药组为60%(95%CI 47.8-72.9)。
- 联合治疗组中位PFS为10.8个月(95%CI 5.6-12.7),单药组为6.5个月(95%CI 5.4-8.5),HR 0.69(95%CI 0.4-1.1),探索性P=0.12。
- 探索性分析显示既往内分泌治疗>6个月亚组联合治疗PFS获益(HR 0.53,95%CI 0.3-0.9,探索性P=0.02),≤6个月亚组未见获益。
临床怎么用
- Palbociclib单药可作为中等程度经治ER阳性/HER2阴性晚期乳腺癌的治疗选择之一。
- 对于既往内分泌治疗有持久缓解(>6个月)的患者,Palbociclib联合既往内分泌治疗可能带来PFS获益。
局限性
- PFS差异为探索性分析,未达统计学显著(探索性P=0.12)。
- 亚组分析为探索性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis has not been evaluated in previous clinical studies. This phase II, open-label, multicenter study examined the activity of palbociclib monotherapy, as well as palbociclib given in combination with the same endocrine therapy (ET) that was received prior to disease progression, in postmenopausal women with moderately pretreated, estrogen receptor-positive, HER2 negative advanced breast cancer. PATIENTS AND METHODS: Eligible women with advanced disease which had progressed on one or two prior ETs were randomized 1 : 1 to receive either palbociclib alone, or palbociclib in combination with the ET as previously received. Primary end point was clinical benefit rate (CBR); secondary end points included progression-free survival (PFS). RESULTS: Between October 2012 and July 2016, a total of 115 patients were randomized. The CBR was 54% [95% confidence interval (CI): 41.5-63.7] for combination therapy, and 60% (95% CI: 47.8-72.9) for monotherapy. Median PFS was 10.8 months (95% CI: 5.6-12.7) for combination therapy, and 6.5 months (95% CI: 5.4-8.5) for monotherapy [hazard ratio (HR) 0.69; 95% CI: 0.4-1.1, exploratory P-value = 0.12]. Exploratory analyses revealed the PFS advantage for combination therapy was seen in the subgroup of patients who received prior ET for >6 months (HR 0.53; 95% CI: 0.3-0.9, exploratory P-value = 0.02), but not in those who received prior ET for ≤6 months. CONCLUSION: Palbociclib has clinical activity as a single agent in women with moderately pretreated, oestrogen receptor-positive, HER2-negative advanced breast cancer. Palbociclib may have potential to reverse endocrine resistance in patients with a history of previous durable response to ET. CLINICAL TRIAL INFORMATION: NCT02549430.
引用
- Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018. PMID: 29893790. doi:10.1093/annonc/mdy214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。